Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Lecanemab is a monoclonal antibody with high affinity to amyloid-beta soluble protofibrils. It was approved in 2023 as an IV ...

Investing.com -- Eisai Co (OTC: ESAIY ). stock rose 0.4% on the day after initially trading in the red, as investors digested the company’s quarterly results that showed strong growth in sales of its ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

With two molecules in mid-stage trials, the pharma giant is taking another swing at the difficult disease with a greater ...

Eisai Europe’s headquarters were expanded to become Eisai Europe, Middle East, Africa and Russia in March 2012. Gary joined Eisai in 2008 as European Commercial Development Director.

After beating quarterly earnings expectations and raising its full-year sales outlook from a previously forecast decline, ...

Japanese drugmaker Eisai said on Tuesday it was targeting revenue of 10 billion yen ($66.5 million) from its recently approved Alzheimer's drug, Leqembi, by March 2024.

CHICAGO, Sept 30 (Reuters) - Clear evidence this week that Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab drug lecanemab slows cognitive decline in early stage dementia has ...